Diabetes and Hyperglycemia Affect Platelet GPIIIa Expression: Effects on Adhesion Potential of Blood Platelets from Diabetic Patients under In Vitro Flow Conditions

Abstract

Blood platelets play a crucial role in the early stages of atherosclerosis development. The process is believed to require firm adhesion of platelets to atherosclerosis-prone sites of the artery. However, little evidence exists regarding whether the blood platelets of individuals with pathological conditions associated with atherosclerosis have higher potential for adhesion. This process is to a large extent dependent on receptors present on the platelet membrane. Therefore, the aim of the presented study was to determine whether blood platelets from diabetic patients have higher capacity of adhesion under flow conditions and how diabetes affects one of the crucial platelet receptors involved in the process of adhesion—GPIIIa. The study compares the ability of platelets from non-diabetic and diabetic humans to interact with fibrinogen and von Willebrand factor, two proteins found in abundance on an inflamed endothelium, under flow conditions. The activation and reactivity of the blood platelets were also characterized by flow cytometry. Platelets from diabetic patients did not demonstrate enhanced adhesion to either studied protein, although they presented increased basal activation and responsiveness towards low concentrations of agonists. Platelets from diabetic patients were characterized by lower expression of GPIIIa, most likely due to an enhanced formation of platelet-derived microparticles PMPs, as supported by the observation of elevated concentration of this integrin and of GPIIIa-positive PMPs in plasma. We conclude that altered functionality of blood platelets in diabetes does not increase their adhesive potential. Increased glycation and decrease in the amount of GPIIIa on platelets may be partially responsible for this effect. Therefore, higher frequency of interactions of platelets with the endothelium, which is observed in animal models of diabetes, is caused by other factors. A primary cause may be a dysfunctional vascular wall.

Platelet adhesion in type 2 diabetes: impact of plasma albumin and mean platelet volume

“…With various surfaces and soluble activators, there were no difference in basal adhesion to the different surfaces upon comparison between controls and T2D subjects in the present study. This result agrees with few earlier studies on adhesion of platelets from diabetic patients using different preparations and assays [ 27 , 28 ].…”

Potential Role of Mitochondria as Modulators of Blood Platelet Activation and Reactivity in Diabetes and Effect of Metformin on Blood Platelet Bioenergetics and Platelet Activation

“…Diabetes mellitus (DM) and uncontrolled hyperglycemia are well-recognized risk factors for the development of cardiovascular diseases, which are the major causes of death amongst patients with DM [ 1 ]. Diabetic patients are characterized by hyperactive platelets with exaggerated adhesion, aggregation and thrombin generation, and these features may also play a role in the development of cardiovascular events [ 2 , 3 ]. However, the mechanisms underlying elevated platelet activation and their hypersensitivity to stimulating factors in this condition remain obscure.…”

Immunometabolic bases of type 2 diabetes in the severity of COVID-19

“…IL-6 increases thrombopoietin production, which enhances proliferation and expansion of thrombotic precursors and leads to thrombocytosis[ 154 ]. Similarly, P2Y12, a receptor expressed on the surface of platelets that plays essential roles in platelet activation, may be elevated in T2D patients, and facilitate platelet adhesion to vascular endothelium[ 155 , 156 ]. Consistent with these findings, numerous reports have demonstrated that the prothrombotic state can be mitigated by lowering blood glucose concentration[ 154 ].…”